Rxulti is indicated for the treatment of schizophrenia in adult and adolescents aged 13 years and older.
REXULTI — OTSUKA, approved 2026-04-30 (NDA205422).
11,375 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.